NovaBay Pharmaceuticals, Inc. Form 8-K June 18, 2015

## **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

**Securities Exchange Act of 1934** 

Date of earliest event reported: June 12, 2015

NovaBay Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

| Delaware                     | 001-33678                | 68-0454536      |
|------------------------------|--------------------------|-----------------|
|                              |                          | ( <b>I.R.S.</b> |
| (State or Other Jurisdiction |                          | Employer        |
|                              | (Commission File Number) |                 |
| of Incorporation)            |                          | Identification  |
|                              |                          | No.)            |

5980 Horton Street, Suite 550, Emeryville, CA 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 899-8800

## (Registrant's telephone number, including area code)

## (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 5.07. Submission of Matters to a Vote of Security Holders

NovaBay Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on June 12, 2015. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast for or withheld in the case of election of directors, and for or against each other matter, and the number of abstentions and broker non-votes with respect to each matter.

1. NovaBay's stockholders elected each of the two Class II directors proposed by NovaBay for re-election, to serve until NovaBay's 2018 Annual Meeting of Stockholders or until his respective successor has been elected and qualified. The tabulation of votes on this matter was as follows:

| Nominee               | Shares         | Shares   |
|-----------------------|----------------|----------|
|                       | Voted For      | Withheld |
| T. Alex McPherson     | 22,250,256     | 567,339  |
| LI Xinzhou ("Paul Li" | ) 22, 154, 663 | 662,932  |

There were 21,510,651 broker non-votes for this proposal.

2. NovaBay's stockholders ratified the selection of OUM & Co. LLP as the independent registered public accounting firm of NovaBay for its fiscal year ending December 31, 2015. The tabulation of votes on this matter was as follows:

| Shares voted for:     | 42,959,719 |
|-----------------------|------------|
| Shares voted against: | 723,604    |
| Shares abstaining:    | 644,923    |
| Broker non-votes:     | 0          |

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### NovaBay Pharmaceuticals, Inc.

(Registrant)

By: /s/ Thomas J. Paulson Thomas J. Paulson Chief Financial Officer, Secretary and Treasurer

Dated: June 18, 2015